Articles tagged with Drug Therapy
Classifying high risk has become a disease in itself, undermining preventive medicine efforts. Doctors and patients often lack understanding of what constitutes high risk and the anticipated treatment benefit, leading to ineffective prevention strategies.
A new study suggests that intravitreous ranibizumab injections may be a reasonable treatment alternative to panretinal photocoagulation (PRP) at least through 2 years for patients with proliferative diabetic retinopathy. The study found that ranibizumab met noninferiority outcomes in visual acuity change compared to PRP.
Researchers found that adding exposure and response prevention therapy to treatment regimens significantly improved symptoms in patients with OCD who had not responded to medication. The study also showed significant increases in insight, quality of life, and social function after just eight weeks.
A new study published in Annals of Behavioral Medicine suggests that behavioral interventions can lead to significant improvements in cardiovascular health. The research indicates that small behavioral changes can have a substantial impact on physical health outcomes.
Treatment with anti-angiogenesis drugs improves radiation treatment of nervous system tumors in animal models, reducing tumor size and nerve damage. Anti-VEGF treatment enhances nerve regeneration and decreases muscle atrophy.
A new study published in the American Journal of Psychiatry suggests that cognitive-behavioral therapy (CBT) is more effective than light therapy in preventing relapse of seasonal affective disorder (SAD). CBT was found to be significantly better at preventing depression recurrence, with only 27% of subjects experiencing symptoms compa...
Researchers have developed a radiotherapeutic bandage that has shown promise as an alternative therapy for squamous cell carcinoma (SCC) in an animal model. The bandages, which are made with nanoparticles containing inactivated radioactive material, can be individually tailored and manufactured on a large scale.
Researchers developed a new method to grow 3D pancreatic tumor cultures from patients' surgical tissue, recreating the patient's cancer biology and morphology. This approach can help identify patient-specific sensitivities to novel therapeutics and assist in making treatment decisions.
Researchers review emerging magnetic particle-based techniques to track cells in vivo, providing a promising concept for treating diseases. The techniques can be used for cell therapy, combining diagnosis and treatment.
Only 27% of older patients with diabetes underwent medication deintensification due to very low hemoglobin A1c levels or blood pressure values. Treatment was deintensified in 16% of those with moderately low and 18.8% of those with very low blood pressure levels. The study suggests that medication deintensification is underutilized, pa...
Scientists create a 'sense' DNA drug that can undo the effects of an antisense drug used to treat blood clots. The new approach reversed the antisense drug's activity and restored normal levels of prothrombin, preventing bleeding. This breakthrough demonstrates the feasibility of using oligonucleotides to target specific genes.
Researchers at University of Liverpool discover that ethosuximide can protect against progressive nerve damage and loss in Parkinson's, Alzheimer's and Huntington's diseases. The study suggests the potential for repurposing ethosuximide as a treatment for multiple neurodegenerative diseases.
Scientists at Cardiff University have discovered a key protein that regulates inflammation in rheumatoid arthritis, enabling the development of tailored treatment plans. This breakthrough has the potential to improve disease outcomes and quality of life for patients with this debilitating condition.
A new study found that people who inject drugs with chronic HCV infection will experience moderate liver fibrosis between 26-38 years after infection and develop cirrhosis within 34-46 years. The disease can lead to hepatocellular carcinoma in mid-to-late adulthood, resulting in a poor prognosis.
A multicenter clinical trial led by Mount Sinai researchers found that brodalumab achieved a 100 percent reduction in psoriasis symptoms, exceeding the results of ustekinumab. The study demonstrated that targeting the IL-17 receptor is highly effective in treating moderate to severe plaque psoriasis.
Researchers at OSU create a new approach to treat eczema and inflammatory skin disorders by identifying specific lipid deficiencies in each person. This system uses advanced science and mass spectrometry to develop personalized treatments.
A new clinical trial has found that cabozantinib, a second-line therapy, controls the growth of advanced kidney cancer more effectively than everolimus. The results show improved progression-free survival and lower tumor growth rates, indicating potential for prolonged survival.
Investigators found that inhibiting TNFR2 can alleviate intestinal inflammation in mice, suggesting a new therapeutic approach for patients with IBD who do not respond to anti-TNF medications. This discovery could lead to new treatment options for the 65% of individuals with IBD who do not respond or become resistant to current therapies.
A review of 54 studies from 20 countries found that people in addiction treatment have a much higher smoking rate, 84% vs 31%, for the general population. The study suggests that addressing tobacco use is crucial to improve substance treatment outcomes.
A new method for testing human induced pluripotent stem cells (iPSCs) has been developed, allowing for the evaluation of their differentiation potential. This approach uses pathway activation profiling to identify impaired iPSC lines and predict in vitro differentiation capabilities.
Researchers at the University of Manchester have discovered a potential new approach to overcome hormone therapy resistance in ER+ breast cancer by targeting breast cancer stem cells driven by NOTCH4. This approach shows promise in improving treatment outcomes for patients with hormone therapy-resistant breast cancer.
A new study suggests that expanding treatment programs to include preschool children and adults is more beneficial, reducing transmission and disability. The study found that a broader scope of treatment would be cost-effective, with an incremental cost-effectiveness ratio of $167.
A five-year programme will focus on developing miniscule technology to deliver drugs directly to cancer sites, improving chemotherapy effectiveness. The project tackles an important area around drug delivery in pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.
Researchers found that coronary spasm at sites of atherosclerotic coronary artery narrowing significantly increases the risk of future heart attacks. Patients with these spasms are more likely to experience acute coronary syndrome, emphasizing the importance of monitoring and preventative therapy.
Researchers at Columbia University developed a new method for targeted drug delivery to the lung, which may provide more effective treatments for many lung diseases. By delivering small volumes of drugs directly to the pathologic site, they aim to reduce adverse effects on other organs.
The new guidelines introduce a novel treatment algorithm for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), recommending sequential and initial combination therapies based on patient risk profiles. The guidelines also provide updated classifications, diagnostic algorithms, and assessmen...
The ESC recommends DNA analysis in post mortems of young sudden death victims to identify genetic causes and facilitate early diagnosis of relatives. This approach helps protect them through personalized approaches, such as lifestyle modifications and therapies.
A new study published in the American Journal of Psychiatry has discovered a predictive fMRI-derived measure that significantly predicts patients' response to antipsychotic medication. This breakthrough enables the use of brain scans as a tool for guiding treatment and improving patient outcomes.
Computer models of developing cancers show that small cell movements can quickly alter tumor composition. The models suggest treatments targeting these movements could slow disease progress by preventing certain cells from flourishing.
A new delayed-release metformin treatment has been developed to target the lower bowel and limit absorption into the blood. The treatment may help 40% of type 2 diabetes patients who currently can't take metformin due to impaired kidney function.
Researchers develop a targeted hydrogel that binds to inflamed tissue, releasing medicine slowly over time. The gel reduces inflammation and minimizes systemic side effects in preclinical models of IBD.
A study analyzed clinical evidence of high-risk therapeutic devices approved through the FDA PMA pathway between 2010 and 2011, finding significant variation in the number and quality of premarket and postmarket studies. Only a few studies were completed, often focusing on surrogate markers and short periods of follow-up.
Scientists from the Scripps Research Institute have developed a new therapy that selectively erases drug-associated memories, preventing relapse in animal models of methamphetamine addiction. The treatment, which involves a single injection of blebbistatin, successfully disrupted long-term storage of drug-related memories and blocked r...
The Endocrine Society recommends tumor removal as the first-line treatment for endogenous Cushing's syndrome. This approach is optimal because it preserves the hypothalamic-pituitary-adrenal axis, which is crucial for the body's central stress response. Other treatment options include medication and radiation therapy.
Researchers discuss emerging antischistosomal drug candidates and address clinical resistance concerns. Praziquantel, the current 'wonder drug,' is being reevaluated due to its drawbacks and potential for clinical resistance.
Researchers used a powerful X-ray laser to create a three-dimensional map of a key protein complex, revealing its structure and interactions. This breakthrough provides insights into developing more targeted therapies for diseases like cancer and heart disease.
Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug. Treatment led to dramatic improvement in itch, sleep, and skin redness, offering hope for a new standard of care for the chronic condition.
Lithium chloride has been shown to prevent cartilage degradation and loss of mechanical integrity associated with osteoarthritis. This breakthrough finding offers a novel potential treatment option for the devastating condition affecting over a third of people over 45 in the UK.
Researchers discovered that age affects the interaction between Interleukin-2 and human mesenchymal stem cells. In younger patients, IL-2 and MSCs work together to fight cancer, but older populations see impaired treatment outcomes.
University of Michigan researchers created a computer model that predicts the flow of liquid medication in human lungs, providing new insight into treating acute respiratory distress syndrome. The model suggests using a less concentrated version of the medication and optimizing its delivery based on individual patient characteristics.
Patients over 50 with ulcerative colitis who undergo elective colectomy live longer than those treated with medications, according to a new study. The study found that surgery was associated with an improved survival rate, particularly in patients age 50 and over.
A new trial by Cancer Research UK has shown that omitting doxorubicin from treatment for children with stage II-III, intermediate-risk Wilms' tumour can be done safely without affecting survival chances. This reduces the risk of irreversible heart problems in later life.
A new study reveals wide geographic variation in use of clotbuster treatment for stroke, with some regions providing treatment to nearly all patients and others giving none. This disparity can lead to unnecessary disability and higher costs for stroke survivors.
A small pilot study found an experimental treatment approach can send deadly leukemia into remission in patients who have failed standard therapy. The combination of immunotherapy and gene manipulation buys critical time for patients to receive a potentially life-saving stem cell transplant.
Researchers at Johns Hopkins Medicine identified a potent seizure inhibitor in mice using D-leucine, an amino acid found in many foods and certain bacteria. The amino acid interrupts prolonged seizures effectively without sedative side effects, paving the way for new treatments for drug-resistant epilepsy.
Children with lower vitamin D levels had higher blood markers related to kidney dysfunction and greater kidney function loss over time. Maintaining normal vitamin D levels helps preserve kidney function in children with CKD.
The combination treatment induced objective responses in 67% of patients with small cell lung cancer, including 10% complete responses. Durable responses were observed, with an overall progression-free survival of 4.6 months.
Researchers at Penn's Abramson Cancer Center have made significant advancements in treating advanced BRCA-related ovarian cancer, with over a third of patients responding to olaparib. Additionally, targeted therapy everolimus shows promise in stabilizing disease for advanced thyroid cancer patients who stop responding to sorafenib, and...
Nivolumab has shown promise as a therapeutic agent for improving survival rates in melanoma patients. The most common adverse events were fatigue, pruritus, diarrhea, and rash, which were primarily low-grade and manageable with immunomodulatory agents.
Researchers have identified molecules associated with Alzheimer's disease as crucial players in long-term depression, a process that weakens synapse connections. These findings suggest potential therapeutic targets for the treatment of Alzheimer's and other neurodegenerative diseases.
The rapidly emerging field of precision medicine is characterized by its use of genetic, biomarker, and psychosocial characteristics to tailor treatments for individual patients. While it holds great promise, precision medicine also raises concerns about the balance between patient needs and fiscal management.
The dominant approach to hip fracture prevention is neither viable nor cost-effective, according to experts. The focus on drug treatment overlooks feasible alternative strategies like physical activity, which can have little to do with osteoporosis but are often overlooked.
Researchers have discovered a promising new treatment for Ebola by screening compounds from existing malaria and flu drugs. The treatment showed a high success rate of up to 90% in treating infected mice with no observable side effects.
Scientists at Northwestern University have synthesized four new chemical compounds with antipsychotic properties using natural products from plant species used in traditional healing practices in Nigeria. These compounds show promise in improving cognitive impairment in animal models, a partially effective treatment for schizophrenia.
Scientists at the University of Montreal discover that a protein in the Rift Valley fever virus mimics human DNA repair factors, making it vulnerable to drug therapy. This breakthrough could lead to new treatments for deadly tropical infections such as Ebola.
Researchers successfully restored bilirubin levels to those found in healthy animals using gene therapy, offering new hope for the treatment of Crigler-Najjar syndrome. The therapy involved transferring a copy of the UGT1A1 gene into liver cells using an AAV vector, resulting in long-term correction without immunosuppression.
Researchers develop a mathematical platform to compute optimal diagnostic-guided vs. pro-active treatment strategies, showing that pro-active strategies may be worthwhile in resource-constrained settings. The study challenges current treatment paradigms and provides a framework for future research.
A new targeted therapy drug rociletinib demonstrates significant activity against treatment-resistant EGFR-mutant lung tumors, improving outcomes for patients with advanced tumors. The drug showed promising results in patients with T790M-driven resistance, resulting in tumor shrinkage and symptom relief.
A new study has discovered specific genetic variants associated with higher risks of increased disease severity in rheumatoid arthritis. Certain amino acid positions in the HLA-DRB1 gene were found to be strong predictors of radiological damage, enabling early identification and potential treatment optimization.
Researchers at James Cook University are conducting a clinical trial to test the effectiveness of intravenous Levetiracetam in treating Convulsive Status Epilepticus (CSE) in children. The study aims to determine if this new treatment can work faster and have fewer serious side effects than current medications.